Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

DTx Pharma

DTx Pharma
2017 FOUNDED
PRIVATE STATUS
Early Stage VC LATEST DEAL TYPE
4 INVESTORS
Description

Developer of RNA-based therapeutics designed to serve as the modality of choice for personalized treatment across most therapeutic areas. The company's therapeutics enable efficient delivery of nucleic acid drugs to tissues throughout the body, enabling healthcare industry to deliver oligos in vivo at therapeutically relevant doses that works in many cell types including neurons, endothelial and T cells.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Primary Office
  • 3210 Merryfield Row
  • San Diego, CA 92121
  • United States

+1 (858) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore DTx Pharma’s full profile, request a free trial.

DTx Pharma Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC Completed Startup
2. Accelerator/Incubator 01-Dec-2017 Completed Startup
1. Accelerator/Incubator 01-Aug-2017 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

DTx Pharma Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Connect Springboard San Diego Accelerator/Incubator Minority 000 0000 000000 0
JLABS Accelerator/Incubator 000 0000 000000 0
San Diego Venture Group Venture Capital Minority 000 0000 000000 0
Tech Coast Angels Angel Group Minority 000 0000 000000 0

DTx Pharma Executive Team (4)

Name Title Board
Seat
Contact
Info
Arthur Suckow Ph.D Chief Scientific Officer & Interim Chief Executive Officer
Jeffrey Friedman MD Chief Operating Officer
Adam Pavlicek Ph.D Co-Founder
John Grundy Ph.D Co-Founder